THERAPEUTIC COMBINATIONS

• US 20070134324A1
• Filed: 01/22/2007
• Published: 06/14/2007
• Est. Priority Date: 07/22/2004
• Status: Abandoned Application

• Current Assignee: Jallal Messadek
• Original Assignee: Jallal Messadek
• Inventors: Messadek, Jallal
• Application Number:
  US11/625,448
• Publication Number:
  US 20070134324A1
• Time in Patent Office: Days
• US Class Current: 424/464
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The goal of the present invention is a pharmaceutical composition including a betaine and an anti-cholesterol agent. The association and co-administration of at least a betaine allows to reducing side effects related to anti-cholesterol agents administration, in particular their deleterious effects on liver, pancreas and kidneys.

Claims

1. A pharmaceutical composition for oral administration comprising:

(1) at least a pharmaceutically acceptable betaine, its pharmaceutically acceptable salts, and their mixtures, said betaine and salts thereof being in a form selected from the group consisting of release controlled form, delay release form, floating form, forms ready to be floating in contact with the gastric medium, forms ready to be floating in contact with the intestinal medium, and combinations thereof, and

(2) at least an anti-cholesterol agent selected from the group consisting of;

A) pharmaceutically acceptable fibrates and pharmaceutically acceptable salts thereof;

B) pharmaceutically acceptable statins and pharmaceutically acceptable salts thereof;

C) pharmaceutically acceptable niacins and pharmaceutically acceptable salts thereof;

D) pharmaceutically acceptable bile sequestering agent and pharmaceutically acceptable salts thereof, and

E) mixtures of these.

2. The composition of claim 1, in which the pharmaceutically acceptable fibrate is selected from the group consisting of befibrates, bezafibrates, ciprofibrates, clofibrates, fenofibrate, pyridoxine, clofibrides, pharmaceutically acceptable salts thereof, and mixtures thereof.

3. The composition of claim 2, in which the pharmaceutically acceptable fibrate is selected from the group consisting of clofibrates, calcium clofibrates, aluminium clofibrates, pyridoxin clofibrates, clofibrides, fenofibrates, micronized fenofibrates, nanonized fenofibrates, gemfibrozils, and mixtures thereof.

4. The composition of claim 1, in which the pharmaceutically acceptable statin is selected from the group consisting of statins, such as atorvastatin calcium, cerivastatin, sodium, fluvastatin sodium, lovastatin, pravastatin sodium, simvastatin, Pitavastatin Rosuvastatin, pharmaceutically acceptable salts thereof, and mixtures thereof.

5. The composition of claim 1, in which the pharmaceutically acceptable niacin is selected from the group consisting of cholestyramines, colesevelam, colestipol, pharmaceutically acceptable salts thereof, and mixtures thereof.

6. The composition of claim 1, in which the betaine or the pharmaceutically acceptable salt thereof is in a controlled release form ensuring a release of betaine for at least 4 hours after the oral administration.

7. The composition of claim 1, in which the betaine or the pharmaceutically acceptable salt thereof is in a controlled release form ensuring a release of betaine for at least 6 hours after the oral administration.

8. The composition of claim 1, in which the betaine or the pharmaceutically acceptable salt thereof is in a controlled release form ensuring a release of betaine for at least 12 hours after the oral administration.

9. The composition of claim 1, in the form of unit dosage form comprising from 250 mg to 2500 mg of betaine.

10. The composition of claim 1, in the form of unit dosage form comprising from 400 mg to 1200 mg of betaine.

11. The composition of claim 9, in the form of a unit dosage form comprising a pharmaceutically effective amount of a anti-cholesterol agent for ensuring an anti-cholesterol treatment for about 12 hours.

12. The composition of claim 1, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine and a pharmaceutically effective amount of a anti-cholesterol agent for ensuring an anti-cholesterol treatment for about 12 hours.

13. The composition of claim 1, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine and a pharmaceutically effective amount of a anti-cholesterol agent for ensuring an anti-cholesterol treatment for about 24 hours.

14. The composition of claim 1, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine and a pharmaceutically effective amount of a anti-cholesterol agent for ensuring an anti-cholesterol treatment for at least 12 hours.

15. The composition of claim 1, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine, said unit dosage form comprising:

at least one solid or semi solid betaine controlled release form substantially free of said anti-cholesterol agent, and

at least one solid or semi-solid form comprising the anti cholesterol agent.

16. The composition of claim 1, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine, said unit dosage form comprising:

at least one solid or semi solid betaine controlled release form substantially free of said anti-cholesterol agent, and

at least one solid or semi-solid form comprising the anti cholesterol agent, said form being substantially free of betaine.

17. The composition of claim 1, which further comprises a therapeutically acceptable amount of a compound selected from the group consisting of aspirin, di-aspirin, pharmaceutically acceptable salts thereof and mixtures thereof.

18. The composition of claim 1, which comprises a therapeutically effective amount of an anti-cholesterol agent for achieving a determined LDL reduction.

19. The composition of claim 1, which comprises a therapeutically effective amount of an anti-cholesterol agent for achieving a determined LDL reduction, whereby said therapeutically effective amount of the anti-cholesterol agent corresponds to less than 80% of the amount of said anti-cholesterol agent which when administered alone ensures said determined LDL reduction.

20. The composition of claim 1, which comprises a therapeutically effective amount of an anti-cholesterol agent for achieving a determined LDL reduction, whereby said therapeutically effective amount of the anti-cholesterol agent corresponds to less than 60% of the amount of said anti-cholesterol agent which when administered alone ensures said determined LDL reduction.

21. The composition of claim 1, which further comprises a surface active agent different from betaine and betaine salt, whereby the weight ratio betaine/said surface active agent different from betaine and betaine salt is greater than 10.

22. The composition of claim 1, which further comprises a surface active agent different from betaine and betaine salt, whereby the weight ratio betaine/said surface active agent different from betaine and betaine salt is greater than 20.

23. The composition of claim 1, which further comprises a surface active agent different from betaine and betaine salt, whereby the weight ratio betaine/said surface active agent different from betaine and betaine salt is greater than 100.

24. The composition of claim 1, which comprises a therapeutically effective amount of glycine betaine or a pharmaceutically acceptable salt thereof.

25. The composition of claim 1, in which the anti-cholesterol agent is in a form selected from the group consisting of fenofibrate co-micronized with betaine or a salt thereof, fenofibrate nanonized in presence of betaine or a salt thereof, fenofibrate dissolved in betaine or a salt thereof, and mixtures thereof.

26. The composition of claim 1, in which the anti-cholesterol agent is in a form selected from the group consisting of fenofibrate co-micronized with glycine betaine or a salt thereof, fenofibrate nanonized in presence of glycine betaine or a salt thereof, fenofibrate dissolved in glycine betaine or a salt thereof, and mixtures thereof.

27. The composition of claim 1, in which the anti-cholesterol agent is fenofibrate co-micronized with betaine or a salt thereof in particles of less than 1 μ

m.

28. The composition of claim 1, in which the anti-cholesterol agent is fenofibrate co-micronized with glycine betaine or a salt thereof in particles of less than 1 μ

m.

29. The composition of claim 1, in which the anti-cholesterol agent is fenofibrate with an weight average size of less than 1 μ

m.

30. A pharmaceutical composition for oral administration comprising:

(1) at least a pharmaceutically acceptable betaine, its pharmaceutically acceptable salts, and their mixtures, and

(2) at least an anti-cholesterol agent selected from the group consisting of;

A) pharmaceutically acceptable fibrates and pharmaceutically acceptable salts thereof;

B) pharmaceutically acceptable statins and pharmaceutically acceptable salts thereof; and

C) mixtures thereof,

whereby said composition comprises at least partly said anti-cholesterol agent in a form selected from the group consisting of anti-cholesterol agent at least partly dissolved into a phase comprising at least betaine, anti-cholesterol agent contained in a film coating particles comprising betaine, anti-cholesterol agent containing matrix in which betaine is dispersed, anti-cholesterol agent containing matrix comprising a dispersed solid or semi solid form containing betaine, and mixtures thereof.

31. The composition of claim 30, in a form selected from the group consisting of release controlled form, delay release form, floating form, forms ready to be floating in contact with the gastric medium, forms ready to be floating in contact with the intestinal medium, and combinations thereof.

32. The composition of claim 30, in which the pharmaceutically acceptable fibrate is selected from the group consisting of befibrates, bezafibrates, ciprofibrates, clofibrates, fenofibrate, pyridoxine, clofibrides, pharmaceutically acceptable salts thereof, and mixtures thereof.

33. The composition of claim 30, in which the pharmaceutically acceptable fibrate is selected from the group consisting of clofibrates, calcium clofibrates, aluminium clofibrates, pyridoxin clofibrates, clofibrides, fenofibrates, micronized fenofibrates, nanonized fenofibrates, gemfibrozils, and mixtures thereof.

34. The composition of claim 30, in which the pharmaceutically acceptable statin is selected from the group consisting of statins, such as atorvastatin calcium, cerivastatin, sodium, fluvastatin sodium, lovastatin, pravastatin sodium, simvastatin, Pitavastatin Rosuvastatin, pharmaceutically acceptable salts thereof, and mixtures thereof.

35. The composition of claim 30, in which the betaine or the pharmaceutically acceptable salt thereof is in a controlled release form ensuring a release of betaine for at least 4 hours after the oral administration.

36. The composition of claim 30, in which the betaine or the pharmaceutically acceptable salt thereof is in a controlled release form ensuring a release of betaine for at least 6 hours after the oral administration.

37. The composition of claim 30, in which the betaine or the pharmaceutically acceptable salt thereof is in a controlled release form ensuring a release of betaine for at least 12 hours after the oral administration.

38. The composition of claim 30, in the form of unit dosage form comprising from 250 mg to 2500 mg of betaine.

39. The composition of claim 30, in the form of unit dosage form comprising from 400 mg to 1200 mg of betaine.

40. The composition of claim 39, in the form of a unit dosage form comprising a pharmaceutically effective amount of a anti-cholesterol agent for ensuring an anti-cholesterol treatment for about 12 hours.

41. The composition of claim 30, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine and a pharmaceutically effective amount of a anti-cholesterol agent for ensuring an anti-cholesterol treatment for about 12 hours.

42. The composition of claim 30, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine and a pharmaceutically effective amount of a anti-cholesterol agent for ensuring an anti-cholesterol treatment for about 24 hours.

43. The composition of claim 30, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine and a pharmaceutically effective amount of a anti-cholesterol agent for ensuring an anti-cholesterol treatment for at least 12 hours.

44. The composition of claim 30, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine, said unit dosage form comprising:

at least one solid or semi solid betaine controlled release form substantially free of said anti-cholesterol agent, and

at least one solid or semi-solid form comprising the anti cholesterol agent.

45. The composition of claim 30, in the form of a unit dosage form comprising from 250 mg to 2500 mg of betaine, said unit dosage form comprising:

at least one solid or semi solid betaine controlled release form substantially free of said anti-cholesterol agent, and

at least one solid or semi-solid form comprising the anti cholesterol agent, said form being substantially free of betaine.

46. The composition of claim 30, comprising less than 300 mg of said anti-cholesterol agent.

47. The composition of claim 30, comprising less than 200 mg of said anti-cholesterol agent.

48. The composition of claim 30, comprising less than 150 mg of said anti-cholesterol agent.

49. The composition of claim 30, comprising less than 120 mg of said anti-cholesterol agent.

50. The composition of claim 30, which further comprises a therapeutically acceptable amount of a compound selected from the group consisting of aspirin, di-aspirin, pharmaceutically acceptable salts thereof and mixtures thereof.

51. The composition of claim 30, which comprises a therapeutically effective amount of an anti-cholesterol agent for achieving a determined LDL reduction.

52. The composition of claim 30, which comprises a therapeutically effective amount of an anti-cholesterol agent for achieving a determined LDL reduction, whereby said therapeutically effective amount of the anti-cholesterol agent corresponds to less than 80% of the amount of said anti-cholesterol agent which when administered alone ensures said determined LDL reduction.

53. The composition of claim 30, which comprises a therapeutically effective amount of an anti-cholesterol agent for achieving a determined LDL reduction, whereby said therapeutically effective amount of the anti-cholesterol agent corresponds to less than 60% of the amount of said anti-cholesterol agent which when administered alone ensures said determined LDL reduction.

54. The composition of claim 30, which further comprises a surface active agent different from betaine and betaine salt, whereby the weight ratio betaine/said surface active agent different from betaine and betaine salt is greater than 10.

55. The composition of claim 30, which further comprises a surface active agent different from betaine and betaine salt, whereby the weight ratio betaine/said surface active agent different from betaine and betaine salt is greater than 20.

56. The composition of claim 30, which further comprises a surface active agent different from betaine and betaine salt, whereby the weight ratio betaine/said surface active agent different from betaine and betaine salt is greater than 100.

57. The composition of claim 30, which comprises a therapeutically effective amount of glycine betaine or a pharmaceutically acceptable salt thereof.

58. The composition of claim 30, in which the anti-cholesterol agent is in a form selected from the group consisting of fenofibrate co-micronized with betaine or a salt thereof, fenofibrate nanonized in presence of betaine or a salt thereof, fenofibrate dissolved in betaine or a salt thereof, and mixtures thereof.

59. The composition of claim 30, in which the anti-cholesterol agent is in a form selected from the group consisting of fenofibrate co-micronized with glycine betaine or a salt thereof, fenofibrate nanonized in presence of glycine betaine or a salt thereof, fenofibrate dissolved in glycine betaine or a salt thereof, and mixtures thereof.

60. The composition of claim 30, in which the anti-cholesterol agent is fenofibrate co-micronized with betaine or a salt thereof in particles of less than 1 μ

m.

61. The composition of claim 30, in which the anti-cholesterol agent is fenofibrate co-micronized with glycine betaine or a salt thereof in particles of less than 1 μ

m.

62. The composition of claim 30, in which the anti-cholesterol agent is fenofibrate with an weight average size of less than 1 μ

m.

63. The composition of claim 30, comprising at least the anti-cholesterol agent at least partly dissolved in a betaine containing phase, whereby said betaine containing phase is solid or semi-solid at least at 30°

C.

64. The composition of claim 30, comprising at least the anti-cholesterol agent at least partly dissolved in a betaine containing phase, whereby said betaine containing phase is solid or semi-solid at least at 40°

C.

65. The composition of claim 30, comprising at least the anti-cholesterol agent at least partly dissolved in a betaine containing phase, whereby said betaine containing phase is solid or semi-solid at least at 55°

C.

66. The composition of claim 63, in which the betaine containing phase has a form selected from the group consisting of tablets, mini tablets, spheroids, extrudats, and spheres.

67. The composition of claim 66, in which the betaine containing phase has a form selected from the group consisting of tablets, mini tablets, spheroids, extrudats, and spheres, said form having an weight average particle size of less than 50 μ

m.

68. The composition of claim 30, comprising:

(a) at least a first phase comprising said anti-cholesterol agent in a form selected from the group consisting of anti-cholesterol agent at least partly dissolved into a phase comprising at least betaine, anti-cholesterol agent contained in a film coating particles comprising betaine, anti-cholesterol agent containing matrix in which betaine is dispersed, anti-cholesterol agent containing matrix comprising a dispersed solid or semi solid form containing betaine, and mixtures thereof, and

(b) a second phase comprising betaine, but substantially free of said anti-cholesterol agent.

69. The composition of claim 30, comprising:

(a) at least a first phase comprising said anti-cholesterol agent in a form selected from the group consisting of anti-cholesterol agent at least partly dissolved into a phase comprising at least betaine, anti-cholesterol agent contained in a film coating particles comprising betaine, anti-cholesterol agent containing matrix in which betaine is dispersed, anti-cholesterol agent containing matrix comprising a dispersed solid or semi solid form containing betaine, and mixtures thereof, and

(b) a second phase comprising betaine, but substantially free of said anti-cholesterol agent, said second phase comprising particles selected from the group consisting of betaine containing particles with an weight average particle size of less than 50 μ

m and particles provided with a betaine containing layer with a thickness of less than 50 μ

m.

70. The composition of claim 30, comprising:

(a) at least a first phase comprising said anti-cholesterol agent in a form selected from the group consisting of anti-cholesterol agent at least partly dissolved into a phase comprising at least betaine, anti-cholesterol agent contained in a film coating particles comprising betaine, anti-cholesterol agent containing matrix in which betaine is dispersed, anti-cholesterol agent containing matrix comprising a dispersed solid or semi solid form containing betaine, and mixtures thereof, and

(b) a second phase comprising betaine, but substantially free of said anti-cholesterol agent, said second phase comprising particles selected from the group consisting of betaine containing particles with an weight average particle size of less than 20 μ

m and particles provided with a betaine containing layer with a thickness of less than 20 μ

m.

71. The composition of claim 30, the betaine containing phase in which the anti cholesterol agent is dissolved is prepared from the drying of an aqueous composition comprising betaine and the anti-cholesterol agent.

72. The composition of claim 30, which further comprises at least one disintegrating agent.

73. The composition of claim 30, which comprises less than 1% by weight of tensioactive agent different from betaine.

74. The composition of claim 30, which is free of sodium lauryl sulfate.

75. The composition of claim 30, in which the weight ratio betaine/anti-cholesterol agent is greater than 2.

76. The composition of claim 30, in which the weight ratio betaine/anti-cholesterol agent is greater than 5.

77. The composition of claim 30, in which the weight ratio betaine/anti-cholesterol agent is comprised between 5 and 50.

78. The composition of claim 30, which comprises:

(a) an immediate release form comprising betaine and the anti-cholesterol agent, and

(b) a betaine containing form selected from the group consisting of release controlled form, delay release form, floating form, forms ready to be floating in contact with the gastric medium, forms ready to be floating in contact with the intestinal medium, and combinations thereof.

79. A method of treatment of a patient suffering or at risk of suffering troubles related to cholesterol, in which said patient is administered a therapeutically effective amount of a pharmaceutical composition for oral administration comprising:

(1) at least a pharmaceutically acceptable betaine, its pharmaceutically acceptable salts, and their mixtures, said betaine and salts thereof being in a form selected from the group consisting of release controlled form, delay release form, floating form, forms ready to be floating in contact with the gastric medium, forms ready to be floating in contact with the intestinal medium, and combinations thereof, and

(2) at least an anti-cholesterol agent selected from the group consisting of;

A) pharmaceutically acceptable fibrates and pharmaceutically acceptable salts thereof,

B) pharmaceutically acceptable statins and pharmaceutically acceptable salts thereof,

C) pharmaceutically acceptable niacins and pharmaceutically acceptable salts thereof;

D) pharmaceutically acceptable bile sequestering agent and pharmaceutically acceptable salts thereof; and

E) mixtures of these.

80. A method of treatment of a patient suffering or at risk of suffering troubles related to cholesterol, in which said patient is administered a therapeutically effective amount of a pharmaceutical composition for oral administration comprising:

(1) at least a pharmaceutically acceptable betaine, its pharmaceutically acceptable salts, and their mixtures, and

(2) at least an anti-cholesterol agent selected from the group consisting of;

A) pharmaceutically acceptable fibrates and pharmaceutically acceptable salts thereof,

B) pharmaceutically acceptable statins and pharmaceutically acceptable salts thereof, and

C) mixtures thereof,

whereby said composition comprises at least partly said anti-cholesterol agent in a form selected from the group consisting of anti-cholesterol agent at least partly dissolved into a phase comprising at least betaine, anti-cholesterol agent contained in a film coating particles comprising betaine, anti-cholesterol agent containing matrix in which betaine is dispersed, anti-cholesterol agent containing matrix comprising a dispersed solid or semi solid form containing betaine, and mixtures thereof.